Lipocine Inc.

Lipocine Inc. ( Lipocine or the Company ) is incorporated under the laws of the State of Delaware. We are a biopharmaceutical company focused on leveraging our proprietary technology platform to develop innovative products with effective oral delivery of previously difficult to deliver molecules. Our proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. Our primary development programs are based on oral delivery solutions for poorly bioavailable drugs. We have a portfolio of differentiated innovative product candidates that target high unmet needs for neurological and psychiatric CNS disorders, liver disease, and hormone supplementation for men and women. On January 12, 2024, we entered into a license agreement (the Verity License Agreement ) with Gordon Silver Limited ( GSL ) and Verity Pharmaceuticals, Inc. ( Verity or our Licensee ), pursuant to which we granted to Verity an exclusive, royalty-bearing, sublicensable right and license to commercialize TLANDO for TRT in the U.S. and Canada (the Licensed Verity Territory ).